|Bid||4.76 x 1000|
|Ask||10.83 x 900|
|Day's Range||10.81 - 10.81|
|52 Week Range||10.03 - 11.10|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MBTC
Nocturne Acquisition Corporation (NASDAQ:MBTC, MBTCU, MBTCR) ("Nocturne"), a publicly-traded special purpose acquisition company, today announced execution of a definitive business combination agreement with Cognos Therapeutics, Inc. ("Cognos"), a medical technology company focused on developing unique, radically advanced devices delivering drugs for the treatment of neurological diseases including brain and spinal cancers, neurodegenerative disorders (such as Alzheimer's and Parkinson's disease
To get a sense of who is truly in control of Nocturne Acquisition Corporation ( NASDAQ:MBTC ), it is important to...
WILMINGTON, DE / ACCESSWIRE / July 5, 2022 / Nocturne Acquisition Corp. (NASDAQ:MBTCU) (the "Company"), announced today that an aggregate of $1,150,000 (the "Extension Payment") has been deposited into the Company's trust account for its public shareholders, representing $0.